II 

Calendar No. Calendar No. 750 

108TH CONGRESS 

2D SESSION S. 2195 

To amend the Controlled Substances Act to clarify the definition of anabolic 

steroids and to provide for research and education activities relating 

to steroids and steroid precursors. 

IN THE SENATE OF THE UNITED STATES 

MARCH 11, 2004 

Mr. BIDEN (for himself, Mr. HATCH, Mr. GRASSLEY, Mr. HARKIN, Mr. STEVENS, Mr. MCCAIN, Mr. NELSON of Florida, Mrs. FEINSTEIN, Mr. 

ALLEN, Ms. MURKOWSKI, and Mr. LAUTENBERG) introduced the following bill; which was read twice and referred to the Committee on the 

Judiciary 

SEPTEMBER 30, 2004 

Reported by Mr. HATCH, with an amendment in the nature of a substitute. 

[Strike out all after the enacting clause and insert the part printed in italic.] 

A BILL 

To amend the Controlled Substances Act to clarify the definition of anabolic steroids and to provide for research 

and education activities relating to steroids and steroid 

precursors. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•S 2195 RS 

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Anabolic Steroid Con3 trol Act of 2004’’. 

4 SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 

5 ACT. 

6 (a) DEFINITIONS.—Section 102 of the Controlled 

7 Substances Act (21 U.S.C. 802) is amended— 

8 (1) in paragraph (41)— 

9 (A) by realigning the margin so as to align 

10 with paragraph (40); and 

11 (B) by striking subparagraph (A) and in12 serting the following: 

13 ‘‘(A) The term ‘anabolic steroid’ means any drug or 

14 hormonal substance, chemically and pharmacologically re15 lated to testosterone (other than estrogens, progestins, 

16 corticosteroids, and dehydroepiandrosterone), and in17 cludes— 

18 ‘‘(i) androstanediol— 

19 ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 

20 ‘‘(II) 3α,17β-dihydroxy-5α-androstane; 

21 ‘‘(ii) androstanedione (5α-androstan-3,17- 

22 dione); 

23 ‘‘(iii) androstenediol— 

24 ‘‘(I) 1-androstenediol (3β,17β-dihydroxy25 5α-androst-1-ene); 
3 

•S 2195 RS 

1 ‘‘(II) 1-androstenediol (3α,17β-dihydroxy2 5α-androst-1-ene); 

3 ‘‘(III) 4-androstenediol (3β,17β-dihydroxy4 androst-4-ene); and 

5 ‘‘(IV) 5-androstenediol (3β,17β-dihydroxy6 androst-5-ene); 

7 ‘‘(iv) androstenedione— 

8 ‘‘(I) 1-androstenedione ([5α]-androst-1-en9 3,17-dione); 

10 ‘‘(II) 4-androstenedione (androst-4-en11 3,17-dione); and 

12 ‘‘(III) 5-androstenedione (androst-5-en13 3,17-dione); 

14 ‘‘(v) bolasterone (7α,17α-dimethyl-17β15 hydroxyandrost-4-en-3-one); 

16 ‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene17 3-one); 

18 ‘‘(vii) calusterone (7β,17α-dimethyl-17β19 hydroxyandrost-4-en-3-one); 

20 ‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4- 

21 en-3-one); 

22 ‘‘(ix) dehydrochloromethyltestosterone (4- 

23 chloro-17β-hydroxy-17α-methyl-androst-1,4-dien-3- 

24 one); 
4 

•S 2195 RS 

1 ‘‘(x) >1-dihydrotestosterone (a.k.a. ‘1-testos2 terone’) (17β-hydroxy-5α-androst-1-en-3-one); 

3 ‘‘(xi) 4-dihydrotestosterone (17β-hydroxy4 androstan-3-one); 

5 ‘‘(xii) drostanolone (17β-hydroxy-2α-methyl-5α6 androstan-3-one); 

7 ‘‘(xiii) ethylestrenol (17α-ethyl-17β-hydroxyestr8 4-ene); 

9 ‘‘(xiv) fluoxymesterone (9-fluoro-17α-methyl10 11β,17β-dihydroxyandrost-4-en-3-one); 

11 ‘‘(xv) formebolone (2-formyl-17α-methyl12 11α,17β-dihydroxyandrost-1,4-dien-3-one); 

13 ‘‘(xvi) furazabol (17α-methyl-17β14 hydroxyandrostano[2,3-c]-furazan); 

15 ‘‘(xvii) 13α-ethyl-17α-hydroxygon-4-en-3-one; 

16 ‘‘(xviii) 4-hydroxytestosterone (4,17β-dihydroxy17 androst-4-en-3-one); 

18 ‘‘(xix) 4-hydroxy-19-nortestosterone (4,17β19 dihydroxy-estr-4-en-3-one); 

20 ‘‘(xx) mestanolone (17α-methyl-17β-hydroxy21 5α-androstan-3-one); 

22 ‘‘(xxi) mesterolone (1α-methyl-17β-hydroxy23 [5α]-androstan-3-one); 

24 ‘‘(xxii) methandienone (17α-methyl-17β25 hydroxyandrost-1,4-dien-3-one); 
5 

•S 2195 RS 

1 ‘‘(xxiii) methandriol (17α-methyl-3β,17β2 dihydroxyandrost-5-ene); 

3 ‘‘(xxiv) methenolone (1-methyl-17β-hydroxy-5α4 androst-1-en-3-one); 

5 ‘‘(xxv) methyltestosterone (17α-methyl-17β6 hydroxyandrost-4-en-3-one); 

7 ‘‘(xxvi) mibolerone (7α,17α-dimethyl-17β8 hydroxyestr-4-en-3-one); 

9 ‘‘(xxvii) 17α-methyl->1-dihydrotestosterone 

10 (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) 

11 (a.k.a. ‘17-α-methyl-1-testosterone’); 

12 ‘‘(xxviii) nandrolone (17β-hydroxyestr-4-en-3- 

13 one); 

14 ‘‘(xxix) norandrostenediol— 

15 ‘‘(I) 19-nor-4-androstenediol (3β, 17β16 dihydroxyestr-4-ene); 

17 ‘‘(II) 19-nor-4-androstenediol (3α, 17β18 dihydroxyestr-4-ene); 

19 ‘‘(III) 19-nor-5-androstenediol (3β, 17β20 dihydroxyestr-5-ene); and 

21 ‘‘(IV) 19-nor-5-androstenediol (3α, 17β22 dihydroxyestr-5-ene); 

23 ‘‘(xxx) norandrostenedione— 

24 ‘‘(I) 19-nor-4-androstenedione (estr-4-en25 3,17-dione); and 
6 

•S 2195 RS 

1 ‘‘(II) 19-nor-5-androstenedione (estr-5-en2 3,17-dione; 

3 ‘‘(xxxi) norbolethone (13β,17α-diethyl-17β4 hydroxygon-4-en-3-one); 

5 ‘‘(xxxii) norclostebol (4-chloro-17β-hydroxyestr6 4-en-3-one); 

7 ‘‘(xxxiii) norethandrolone (17α-ethyl-17β8 hydroxyestr-4-en-3-one); 

9 ‘‘(xxxiv) oxandrolone (17α-methyl-17β-hydroxy10 2-oxa-[5α]-androstan-3-one); 

11 ‘‘(xxxv) oxymesterone (17α-methyl-4,17β12 dihydroxyandrost-4-en-3-one); 

13 ‘‘(xxxvi) oxymetholone (17α-methyl-2- 

14 hydroxymethylene-17β-hydroxy-[5α]-androstan-3- 

15 one); 

16 ‘‘(xxxvii) stanozolol (17α-methyl-17β-hydroxy17 [5α]-androst-2-eno[3,2-c]-pyrazole); 

18 ‘‘(xxxviii) stenbolone (17β-hydroxy-2-methyl19 [5α]-androst-1-en-3-one); 

20 ‘‘(xxxix) testolactone (13-hydroxy-3-oxo-13,17- 

21 secoandrosta-1,4-dien-17-oic acid lactone); 

22 ‘‘(xl) testosterone (17β-hydroxyandrost-4-en-3- 

23 one); 

24 ‘‘(xli) tetrahydrogestrinone (13β,17α-diethyl25 17β-hydroxygon-4,9,11-trien-3-one); 
7 

•S 2195 RS 

1 ‘‘(xlii) trenbolone (17β-hydroxyestr-4,9,11-trien2 3-one); and 

3 ‘‘(xliii) any salt, ester, or ether of a drug or 

4 substance described in this paragraph.’’; and 

5 (2) in paragraph (44), by inserting ‘‘anabolic 

6 steroids,’’ after ‘‘marihuana,’’. 

7 (b) AUTHORITY AND CRITERIA FOR CLASSIFICA8 TION.—Section 201(g) of the Controlled Substances Act 

9 (21 U.S.C. 811(g)) is amended— 

10 (1) in paragraph (1), by striking ‘‘substance 

11 from a schedule if such substance’’ and inserting 

12 ‘‘drug which contains a controlled substance from 

13 the application of titles II and III of the Comprehen14 sive Drug Abuse Prevention and Control Act (21 

15 U.S.C. 802 et seq.) if such drug’’; and 

16 (2) in paragraph (3), by adding at the end the 

17 following: 

18 ‘‘(C) Upon the recommendation of the Sec19 retary of Health and Human Services, a compound, 

20 mixture, or preparation which contains any anabolic 

21 steroid, which is intended for administration to a 

22 human being or an animal, and which, because of its 

23 concentration, preparation, formulation or delivery 

24 system, does not present any significant potential for 

25 abuse.’’. 
8 

•S 2195 RS 

1 (c) ANABOLIC STEROIDS CONTROL ACT.—Section 

2 1903 of the Anabolic Steroids Control Act of 1990 (Public 

3 Law 101–647) is amended— 

4 (1) by striking subsection (a); and 

5 (2) by redesignating subsections (b) and (c) as 

6 subsections (a) and (b), respectively. 

7 SEC. 3. SENTENCING COMMISSION GUIDELINES. 

8 The United States Sentencing Commission shall— 

9 (1) review the Federal sentencing guidelines 

10 with respect to offenses involving anabolic steroids; 

11 (2) consider amending the Federal sentencing 

12 guidelines to provide for increased penalties with re13 spect to offenses involving anabolic steroids in a 

14 manner that reflects the seriousness of such offenses 

15 and the need to deter anabolic steroid trafficking 

16 and use; and 

17 (3) take such other action that the Commission 

18 considers necessary to carry out this section. 

19 SEC. 4. PREVENTION AND EDUCATION PROGRAMS. 

20 (a) IN GENERAL.—The Secretary of Health and 

21 Human Services (referred to in this Act as the ‘‘Sec22 retary’’) shall award grants to public and nonprofit private 

23 entities to enable such entities to carry out science-based 

24 education programs in elementary and secondary schools 

25 to highlight the harmful effects of anabolic steroids. 
9 

•S 2195 RS 

1 (b) ELIGIBILITY.— 

2 (1) APPLICATION.—To be eligible for grants 

3 under subsection (a), an entity shall prepare and 

4 submit to the Secretary an application at such time, 

5 in such manner, and containing such information as 

6 the Secretary may require. 

7 (2) PREFERENCE.—In awarding grants under 

8 subsection (a), the Secretary shall give preference to 

9 applicants that intend to use grant funds to carry 

10 out programs based on— 

11 (A) the Athletes Training and Learning to 

12 Avoid Steroids program; 

13 (B) the Athletes Targeting Healthy Exer14 cise and Nutrition Alternatives program; and 

15 (C) other programs determined to be effec16 tive by the National Institute on Drug Abuse. 

17 (c) USE OF FUNDS.—Amounts received under a 

18 grant under subsection (a) shall be used primarily for edu19 cation programs that will directly communicate with 

20 teachers, principals, coaches, as well as elementary and 

21 secondary school children concerning the harmful effects 

22 of anabolic steroids. 

23 (d) AUTHORIZATION OF APPROPRIATIONS.—There is 

24 authorized to be appropriated to carry out this section, 

25 $15,000,000 for each of fiscal years 2005 through 2010. 
10 

•S 2195 RS 

1 SEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH. 

2 (a) IN GENERAL.—The Secretary of Health and 

3 Human Services shall ensure that the National Survey on 

4 Drug Use and Health includes questions concerning the 

5 use of anabolic steroids. 

6 (b) AUTHORIZATION OF APPROPRIATIONS.—There is 

7 authorized to be appropriated to carry out this section, 

8 $1,000,000 for each of fiscal years 2005 through 2010. 

9 This Act may be cited as the ‘‘Anabolic Steroid Control 

10 Act of 2004’’. 

11 SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 

12 ACT. 

13 (a) DEFINITIONS.—Section 102 of the Controlled Sub14 stances Act (21 U.S.C. 802) is amended— 

15 (1) in paragraph (41)— 

16 (A) by realigning the margin so as to align 

17 with paragraph (40); and 

18 (B) by striking subparagraph (A) and in19 serting the following: 

20 ‘‘(A) The term ‘anabolic steroid’ means any drug or 

21 hormonal substance, chemically and pharmacologically re22 lated to testosterone (other than estrogens, progestins, 

23 corticosteroids, and dehydroepiandrosterone), and in24 cludes— 

25 ‘‘(i) androstanediol— 

26 ‘‘(I) 3β,17β-dihydroxy-5α-androstane; and 
11 

•S 2195 RS 

1 ‘‘(II) 3α,17β-dihydroxy-5α-androstane; 

2 ‘‘(ii) androstanedione (5α-androstan-3,17-dione); 

3 ‘‘(iii) androstenediol— 

4 ‘‘(I) 1-androstenediol (3β,17β-dihydroxy5 5α-androst-1-ene); 

6 ‘‘(II) 1-androstenediol (3α,17β-dihydroxy7 5α-androst-1-ene); 

8 ‘‘(III) 4-androstenediol (3β,17β-dihydroxy9 androst-4-ene); and 

10 ‘‘(IV) 5-androstenediol (3β,17β-dihydroxy11 androst-5-ene); 

12 ‘‘(iv) androstenedione— 

13 ‘‘(I) 1-androstenedione ([5α]-androst-1-en14 3,17-dione); 

15 ‘‘(II) 4-androstenedione (androst-4-en-3,17- 

16 dione); and 

17 ‘‘(III) 5-androstenedione (androst-5-en-3,17- 

18 dione); 

19 ‘‘(v) bolasterone (7α,17α-dimethyl-17β20 hydroxyandrost-4-en-3-one); 

21 ‘‘(vi) boldenone (17β-hydroxyandrost-1,4,-diene22 3-one); 

23 ‘‘(vii) calusterone (7β,17α-dimethyl-17β24 hydroxyandrost-4-en-3-one); 
12 

•S 2195 RS 

1 ‘‘(viii) clostebol (4-chloro-17β-hydroxyandrost-4- 

2 en-3-one); 

3 ‘‘(ix) dehydrochloromethyltestosterone (4-chloro4 17β-hydroxy-17α-methyl-androst-1,4-dien-3-one); 

5 ‘‘(x) >1-dihydrotestosterone (a.k.a. ‘1-testos6 terone’) (17β-hydroxy-5α-androst-1-en-3-one); 

7 ‘‘(xi) 4-dihydrotestosterone (17β-hydroxy8 androstan-3-one); 

9 ‘‘(xii) drostanolone (17β-hydroxy-2α-methyl-5α10 androstan-3-one); 

11 ‘‘(xiii) ethylestrenol (17α-ethyl-17β-hydroxyestr12 4-ene); 

13 ‘‘(xiv) fluoxymesterone (9-fluoro-17α-methyl14 11β,17β-dihydroxyandrost-4-en-3-one); 

15 ‘‘(xv) formebolone (2-formyl-17α-methyl16 11α,17β-dihydroxyandrost-1,4-dien-3-one); 

17 ‘‘(xvi) furazabol (17α-methyl-17β18 hydroxyandrostano[2,3-c]-furazan); 

19 ‘‘(xvii) 13β-ethyl-17α-hydroxygon-4-en-3-one; 

20 ‘‘(xviii) 4-hydroxytestosterone (4,17β-dihydroxy21 androst-4-en-3-one); 

22 ‘‘(xix) 4-hydroxy-19-nortestosterone (4,17β23 dihydroxy-estr-4-en-3-one); 

24 ‘‘(xx) mestanolone (17α-methyl-17β-hydroxy-5α25 androstan-3-one); 
13 

•S 2195 RS 

1 ‘‘(xxi) mesterolone (1α-methyl-17β-hydroxy-[5α]- 

2 androstan-3-one); 

3 ‘‘(xxii) methandienone (17α-methyl-17β4 hydroxyandrost-1,4-dien-3-one); 

5 ‘‘(xxiii) methandriol (17α-methyl-3β,17β6 dihydroxyandrost-5-ene); 

7 ‘‘(xxiv) methenolone (1-methyl-17β-hydroxy-5α8 androst-1-en-3-one); 

9 ‘‘(xxv) 17α-methyl-3β, 17β-dihydroxy-5α-andro10 stane; 

11 ‘‘(xxvi) 17α-methyl-3α,17β-dihydroxy-5α-andro12 stane; 

13 ‘‘(xxvii) 17α-methyl-3β,17β-dihydroxyandrost-4- 

14 ene. 

15 ‘‘(xxviii) 17α-methyl-4-hydroxynandrolone (17α16 methyl-4-hydroxy-17β-hydroxyestr-4-en-3-one); 

17 ‘‘(xxix) methyldienolone (17α-methyl-17β18 hydroxyestra-4,9(10)-dien-3-one); 

19 ‘‘(xxx) methyltrienolone (17α-methyl-17β20 hydroxyestra-4,9-11-trien-3-one); 

21 ‘‘(xxxi) methyltestosterone (17α-methyl-17β22 hydroxyandrost-4-en-3-one); 

23 ‘‘(xxxii) mibolerone (7α,17α-dimethyl-17β24 hydroxyestr-4-en-3-one); 
14 

•S 2195 RS 

1 ‘‘(xxxiii) 17α-methyl->1-dihydrotestosterone 

2 (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one) 

3 (a.k.a. ‘17-α-methyl-1-testosterone’); 

4 ‘‘(xxxiv) nandrolone (17β-hydroxyestr-4-en-3- 

5 one); 

6 ‘‘(xxxv) norandrostenediol— 

7 ‘‘(I) 19-nor-4-androstenediol (3β, 17β8 dihydroxyestr-4-ene); 

9 ‘‘(II) 19-nor-4-androstenediol (3α, 17β10 dihydroxyestr-4-ene); 

11 ‘‘(III) 19-nor-5-androstenediol (3β, 17β12 dihydroxyestr-5-ene); and 

13 ‘‘(IV) 19-nor-5-androstenediol (3α, 17β14 dihydroxyestr-5-ene); 

15 ‘‘(xxxvi) norandrostenedione— 

16 ‘‘(I) 19-nor-4-androstenedione (estr-4-en17 3,17-dione); and 

18 ‘‘(II) 19-nor-5-androstenedione (estr-5-en19 3,17-dione; 

20 ‘‘(xxxvii) norbolethone (13β,17α-diethyl-17β21 hydroxygon-4-en-3-one); 

22 ‘‘(xxxviii) norclostebol (4-chloro-17β-hydroxyestr23 4-en-3-one); 

24 ‘‘(xxxix) norethandrolone (17α-ethyl-17β25 hydroxyestr-4-en-3-one); 
15 

•S 2195 RS 

1 ‘‘(xl) normethandrolone (17α-methyl-17β2 hydroxyestr-4-en-3-one); 

3 ‘‘(xli) oxandrolone (17α-methyl-17β-hydroxy-2- 

4 oxa-[5α]-androstan-3-one); 

5 ‘‘(xlii) oxymesterone (17α-methyl-4,17β6 dihydroxyandrost-4-en-3-one); 

7 ‘‘(xliii) oxymetholone (17α-methyl-2- 

8 hydroxymethylene-17β-hydroxy-[5α]-androstan-3- 

9 one); 

10 ‘‘(xliv) stanozolol (17α-methyl-17α-hydroxy11 [5α]-androst-2-eno[3,2-c]-pyrazole); 

12 ‘‘(xlv) stenbolone (17β-hydroxy-2-methyl-[5α]- 

13 androst-1-en-3-one); 

14 ‘‘(xlvi) testolactone (13-hydroxy-3-oxo-13,17- 

15 secoandrosta-1,4-dien-17-oic acid lactone); 

16 ‘‘(xlvii) testosterone (17β-hydroxyandrost-4-en-3- 

17 one); 

18 ‘‘(xlviii) tetrahydrogestrinone (13β,17α-diethyl19 17β-hydroxygon-4,9,11-trien-3-one); 

20 ‘‘(xlix) trenbolone (17β-hydroxyestr-4,9,11-trien21 3-one); and 

22 ‘‘(xlx) any salt, ester, or ether of a drug or sub23 stance described in this paragraph. 

24 The substances excluded under this subparagraph may at 

25 any time be scheduled by the Attorney General in accord-
16 

•S 2195 RS 

1 ance with the authority and requirements of subsections (a) 

2 through (c) of section 201.’’; and 

3 (2) in paragraph (44), by inserting ‘‘anabolic 

4 steroids,’’ after ‘‘marihuana,’’. 

5 (b) AUTHORITY AND CRITERIA FOR CLASSIFICA6 TION.—Section 201(g) of the Controlled Substances Act (21 

7 U.S.C. 811(g)) is amended— 

8 (1) in paragraph (1), by striking ‘‘substance 

9 from a schedule if such substance’’ and inserting 

10 ‘‘drug which contains a controlled substance from the 

11 application of titles II and III of the Comprehensive 

12 Drug Abuse Prevention and Control Act (21 U.S.C. 

13 802 et seq.) if such drug’’; and 

14 (2) in paragraph (3), by adding at the end the 

15 following: 

16 ‘‘(C) Upon the recommendation of the Secretary 

17 of Health and Human Services, a compound, mix18 ture, or preparation which contains any anabolic 

19 steroid, which is intended for administration to a 

20 human being or an animal, and which, because of its 

21 concentration, preparation, formulation or delivery 

22 system, does not present any significant potential for 

23 abuse.’’. 
17 

•S 2195 RS 

1 (c) ANABOLIC STEROIDS CONTROL ACT.—Section 

2 1903 of the Anabolic Steroids Control Act of 1990 (Public 

3 Law 101–647) is amended— 

4 (1) by striking subsection (a); and 

5 (2) by redesignating subsections (b) and (c) as 

6 subsections (a) and (b), respectively. 

7 (d) EFFECTIVE DATE.—The amendments made by this 

8 section shall take effect 90 days after the date of enactment 

9 of this Act. 

10 SEC. 3. SENTENCING COMMISSION GUIDELINES. 

11 The United States Sentencing Commission shall— 

12 (1) review the Federal sentencing guidelines with 

13 respect to offenses involving anabolic steroids; 

14 (2) consider amending the Federal sentencing 

15 guidelines to provide for increased penalties with re16 spect to offenses involving anabolic steroids in a man17 ner that reflects the seriousness of such offenses and 

18 the need to deter anabolic steroid trafficking and use; 

19 and 

20 (3) take such other action that the Commission 

21 considers necessary to carry out this section. 

22 SEC. 4. PREVENTION AND EDUCATION PROGRAMS. 

23 (a) IN GENERAL.—The Secretary of Health and 

24 Human Services (referred to in this Act as the ‘‘Secretary’’) 

25 shall award grants to public and nonprofit private entities 
18 

•S 2195 RS 

1 to enable such entities to carry out science-based education 

2 programs in elementary and secondary schools to highlight 

3 the harmful effects of anabolic steroids. 

4 (b) ELIGIBILITY.— 

5 (1) APPLICATION.—To be eligible for grants 

6 under subsection (a), an entity shall prepare and sub7 mit to the Secretary an application at such time, in 

8 such manner, and containing such information as the 

9 Secretary may require. 

10 (2) PREFERENCE.—In awarding grants under 

11 subsection (a), the Secretary shall give preference to 

12 applicants that intend to use grant funds to carry out 

13 programs based on— 

14 (A) the Athletes Training and Learning to 

15 Avoid Steroids program; 

16 (B) The Athletes Targeting Healthy Exer17 cise and Nutrition Alternatives program; and 

18 (C) other programs determined to be effec19 tive by the National Institute on Drug Abuse. 

20 (c) USE OF FUNDS.—Amounts received under a grant 

21 under subsection (a) shall be used primarily for education 

22 programs that will directly communicate with teachers, 

23 principals, coaches, as well as elementary and secondary 

24 school children concerning the harmful effects of anabolic 

25 steroids. 
19 

•S 2195 RS 

1 (d) AUTHORIZATION OF APPROPRIATIONS.—There is 

2 authorized to be appropriated to carry out this section, 

3 $15,000,000 for each of fiscal years 2005 through 2010. 

4 SEC. 5. NATIONAL SURVEY ON DRUG USE AND HEALTH. 

5 (a) IN GENERAL.—The Secretary of Health and 

6 Human Services shall ensure that the National Survey on 

7 Drug Use and Health includes questions concerning the use 

8 of anabolic steroids. 

9 (b) AUTHORIZATION OF APPROPRIATIONS.—There is 

10 authorized to be appropriated to carry out this section, 

11 $1,000,000 for each of fiscal years 2005 through 2010. 
Calendar No. 750 

108TH CONGRESS 

2D SESSION S. 2195 

A BILL 

To amend the Controlled Substances Act to clarify 

steroids and steroid precursors. for research and education activities relating to the definition of anabolic steroids and to provide 

SEPTEMBER 30, 2004 

Reported with an amendment